Combining the specific targeting of antigens via CAR‐T cells or CAR‐NK cells along with a STING agonist creates an effective therapeutic strategy, as this approach could amplify the trafficking of CAR‐transduced cells to the tumor site and further increase their anti‐tumoral activity. This evidence concerns the gene STING1 and neoplasm.